Reaffirms commitment to maintaining CN’s U.S. headquarters in Kansas City and ongoing investment in local communities
Proposed combination will provide the ability for customers to choose the best route and carrier options for their needs
MONTREAL, May 03, 2021 (GLOBE NEWSWIRE) — CN (TSX: CNR, NYSE: CNI) today issued an open letter to the Kansas City Southern (NYSE: KSU) (“KCS”) community regarding CN’s superior proposal to combine with KCS. The letter outlines why a combined CN-KCS represents the best solution for all stakeholders and sets the record straight on the merits of CN’s proposal.
The following is a copy of the letter:
To the KCS Community,
At CN, we believe how you get there is just as important as reaching your destination. On the railroad, that means getting our customers’ freight from origin to destination safely, cost-effectively and reliably, with respect for the environment and the communities we serve. In business, it means dealing fairly and honestly, with respect for people and processes.
We are in a spirited contest with Canadian Pacific (CP) to acquire Kansas City Southern (KCS). We believe we have a better bid than CP, that we can be a better partner to KCS and all of its stakeholders, and that a combined CN-KCS represents the best solution for shippers and the North American economy.
We also believe that the people who pay to move freight on our rails should have a say in what happens here. That is why we asked our industry regulator – the Surface Transportation Board – to apply a higher “enhanced competition” standard of regulatory review to our proposed transaction instead of the lower pre-2001 standard CP asked for.
We want to know what customers think, and we are confident they will like what they hear. Since launching our bid, more than 600 customers, suppliers, port operators, elected officials and other key stakeholders have written letters to the STB in support of a CN-KCS combination.
Finally, we believe facts matter, and that good processes lead to proper outcomes. And that is why we feel compelled to set the record straight on some of the so-called “truths” that CP has been promoting in an effort to muddy the water on our clearly superior bid. So here are some facts:

With more choices comes more competition, lower costs and better service. A CN-KCS combination will offer customers more connections and more choices, with new access points and gateway options. This includes an additional 22 Class 1 gateways, 5 ports and 10 barge terminals for the supply chain of KCS customers. A combined CP-KCS offers none of this.
CN will preserve all existing route choices. We are committed to preserving routing options by keeping current gateways open and providing bottleneck protections. This empowers customers to choose the best route and carrier options for their needs.
CN is creating new shipping options. CP wants you to believe that a combined CN-KCS would impair competition in north-south shipping. This plainly isn’t true. A combined CN-KCS would compete with multiple Class 1 railroads operating no less than six other north-south routes, not to mention Mississippi River barge traffic and the biggest freight carriers of all – truck traffic along Interstates 35 and 55.
CN is committed to Kansas City Southern – and to Kansas City. We have great respect for KCS’s people, culture and history. We are committed to maintaining CN’s U.S. headquarters in Kansas City, investing in the communities we serve and working with KCS’s talented management team to create good new jobs up and down the line.
CN has committed to implementing appropriate arrangements with its customers and the STB to address any competitive concerns, including those that might arise from the fact that 1% of a combined CN-KCS’s tracks would overlap. At CN, we focus on solutions.
CN has put forward an identical voting trust structure to CP to ensure KCS remains independent until regulators have approved whichever transaction KCS ultimately chooses to pursue. We are confident the STB will approve both voting trusts and put them on level ground so that KCS shareholders can realize the best value for their shares.

These are the facts. You can also read more about this important transaction and our superior proposal at www.ConnectedContinent.com.
CN has been a part of the fabric of the American industrial heartland for decades, with the highly successful acquisitions and integrations of Wisconsin Central, Illinois Central, the EJ&E and other iconic U.S. railroads. We hope we can count on your support so that CN and KCS together can embark on the next phase of the process towards creating the premier railway for the 21st century.
Respectfully,

JJ RuestCEOCN
Rob ReillyCOOCN

For more information about CN’s superior proposal to combine with KCS, please visit www.ConnectedContinent.com.
About CN
CN is a world-class transportation leader and trade-enabler. Essential to the economy, to the customers, and to the communities it serves, CN safely transports more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year. As the only railroad connecting Canada’s Eastern and Western coasts with the U.S. South through a 19,500-mile rail network, CN and its affiliates have been contributing to community prosperity and sustainable trade since 1919. CN is committed to programs supporting social responsibility and environmental stewardship.
Forward Looking Statements
Certain statements included in this news release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and under Canadian securities laws, including statements based on management’s assessment and assumptions and publicly available information with respect to KCS, regarding the proposed transaction between CN and KCS, the expected benefits of the proposed transaction and future opportunities for the combined company. By their nature, forward-looking statements involve risks, uncertainties and assumptions. CN cautions that its assumptions may not materialize and that current economic conditions render such assumptions, although reasonable at the time they were made, subject to greater uncertainty. Forward-looking statements may be identified by the use of terminology such as “believes,” “expects,” “anticipates,” “assumes,” “outlook,” “plans,” “targets,” or other similar words.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors which may cause actual results, performance or achievements of CN, or the combined company, to be materially different from the outlook or any future results, performance or achievements implied by such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements. Important risk factors that could affect the forward-looking statements in this news release include, but are not limited to: the outcome of any possible transaction between CN and KCS, including the possibility that a transaction will not be agreed to or that the terms of any definitive agreement will be materially different from those described; uncertainties as to whether KCS will cooperate with CN regarding the proposed transaction; the parties’ ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction; that the regulatory approvals required for the proposed transaction may not be obtained on the terms expected or on the anticipated schedule or at all; CN’s indebtedness, including the substantial indebtedness CN expects to incur and assume in connection with the proposed transaction and the need to generate sufficient cash flows to service and repay such debt; CN’s ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; the possibility that CN may be unable to achieve expected synergies and operating efficiencies within the expected time-frames or at all and to successfully integrate KCS’ operations with those of CN; that such integration may be more difficult, time-consuming or costly than expected; that operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers or suppliers) may be greater than expected following the proposed transaction or the public announcement of the proposed transaction; the retention of certain key employees of KCS may be difficult; the duration and effects of the COVID-19 pandemic, general economic and business conditions, particularly in the context of the COVID-19 pandemic; industry competition; inflation, currency and interest rate fluctuations; changes in fuel prices; legislative and/or regulatory developments; compliance with environmental laws and regulations; actions by regulators; the adverse impact of any termination or revocation by the Mexican government of KCS de México, S.A. de C.V.’s Concession; increases in maintenance and operating costs; security threats; reliance on technology and related cybersecurity risk; trade restrictions or other changes to international trade arrangements; transportation of hazardous materials; various events which could disrupt operations, including illegal blockades of rail networks, and natural events such as severe weather, droughts, fires, floods and earthquakes; climate change; labor negotiations and disruptions; environmental claims; uncertainties of investigations, proceedings or other types of claims and litigation; risks and liabilities arising from derailments; timing and completion of capital programs; and other risks detailed from time to time in reports filed by CN with securities regulators in Canada and the United States. Reference should also be made to Management’s Discussion and Analysis in CN’s annual and interim reports, Annual Information Form and Form 40-F, filed with Canadian and U.S. securities regulators and available on CN’s website, for a description of major risk factors relating to CN.
Forward-looking statements reflect information as of the date on which they are made. CN assumes no obligation to update or revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, unless required by applicable securities laws. In the event CN does update any forward-looking statement, no inference should be made that CN will make additional updates with respect to that statement, related matters, or any other forward-looking statement.
No Offer or SolicitationThis news release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information and Where to Find ItThis news release relates to a proposal which CN has made for an acquisition of KCS. In furtherance of this proposal and subject to future developments, CN (and, if a negotiated transaction is agreed, KCS) may file one or more registration statements, proxy statements, tender offer statements or other documents with the U.S. Securities and Exchange Commission (“SEC”) or applicable securities regulators in Canada. This news release is not a substitute for any proxy statement, registration statement, tender offer statement, prospectus or other document CN and/or KCS may file with the SEC or applicable securities regulators in Canada in connection with the proposed transactions.

[…]

Read More…

LITTLE FALLS, N.J., May 3, 2021 /PRNewswire/ — Ceragon Networks Ltd. (NASDAQ: CRNT), the global innovator and leading solutions provider of 5G wireless transport, today reported its financial results for the first quarter ended March 31, 2021.
Ira Palti, President & CEO, commented: “2021 has been off to a good start both for the telecom industry in general and for us at Ceragon specifically. The amount of data flowing around the globe has increased at an exponential rate. As Tier-1 and Tier-2 operators step up their efforts to provide enhanced 4G coverage as well as new 5G services, many of them turn to Ceragon.”
“In Q1 2021, the accelerated 5G evolution along with the growing OpenRan movement has kept Ceragon’s growing suite of innovative solutions in the spotlight. We achieved three new 5G design wins, saw very strong bookings across different regions, and were selected to participate in an OpenRan trial in TIM Brazil. Even though the industry is currently facing component shortages, which might affect our short-term deliveries, the global telecom industry is fast moving into a new era and Ceragon is well prepared to excel in it.”
“As the Company’s president & CEO for the last sixteen years, I’ve led the company from a simpler 2G world into today’s more complex OpenRan, 5G world. It’s with peace of mind and a feeling of accomplishment that I pass the keys of the CEO office to our successful former deputy CEO & CFO Doron Arazi. I’ll continue serving Ceragon as vice-chairman of the board starting July.”
Primary First Quarter 2021 Financial Results:
Revenues were $68.3 million, up 22.2% from $55.9 million in Q1 2020 and down 7.7% from $74.0 million in Q4 2020. Our revenues varied from region to region and were in line with the effect that COVID has had on local business operations and network build-out plans.
Gross profit was $20.1 million, giving us a gross margin of 29.5%, compared with a gross margin of 25.1% in Q1 2020 and 29.1% in Q4 2020. The relatively low gross margin reflects continued high supply chain costs due to the COVID-19 environment.
Operating income (loss) was $0.4 million compared with operating loss of $(6.0) million for Q1 2020 and $(1.5) million for Q4 2020.
Net loss was $(1.2) million, or $(0.01) per diluted share compared with $(6.9) million, or $(0.09) per diluted share for Q1 2020 and $(6.3) million, or $(0.08) per diluted share for Q4 2020.
Non-GAAP results were as follows: Gross margin was 29.6%, operating profit was $0.7 million, and net loss was $(0.9) million, or $(0.01) per diluted share.
Cash and cash equivalents was $33.0 million at March 31, 2021, compared to $27.1 million at December 31, 2020.
For a reconciliation of GAAP to non-GAAP results, see the attached tables.
Revenue Breakouts by Geography:

Q1 2021

India

26%

Europe

19%

North America

17%

Latin America

15%

APAC

14%

Africa

9%

Outlook
We continue to target revenue growth in 2021. Although we still expect a slow start for the first half of the year, we continue to expect yearly revenue to be between $275-$295 million. Now all that said, the growing component shortage may have a negative impact on the timeliness of our Q2 and rest-of-the-year deliveries and may lead to a probable push of revenues between quarters until the shortage is resolved.
Conference Call
The Company will host a Zoom web conference today at 9:00a.m. ET to discuss the results, followed by a question and answer session for the investment community.
Investors are invited to register by clicking the following link: https://us02web.zoom.us/webinar/register/WN_ZrHJ225HTJKmGqKKHgWtTA. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at www.ceragon.com within 24 hours after the call.
About Ceragon Networks
Ceragon Networks Ltd. (NASDAQ: CRNT) is the global innovator and leading solutions provider of 5G wireless transport. We help operators and other service providers worldwide increase operational efficiency and enhance end customers’ quality of experience with innovative wireless backhaul and fronthaul solutions. Our customers include service providers, public safety organizations, government agencies and utility companies, which use our solutions to deliver 5G & 4G, mission-critical multimedia services and other applications at high reliability and speed.
Ceragon’s unique multicore technology and disaggregated approach to wireless transport provides highly reliable, fast to deploy, high-capacity wireless transport for 5G and 4G networks with minimal use of spectrum, power, real estate and labor resources. It enables increased productivity, as well as simple and quick network modernization, positioning Ceragon as a leading solutions provider for the 5G era. We deliver a range of professional services that ensure efficient network rollout and optimization to achieve the highest value for our customers. Our solutions are deployed by more than 400 service providers, as well as more than 800 private network owners, in more than 150 countries. For more information please visit: www.ceragon.com
Safe Harbor
Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON ® is a trademark of Ceragon Networks Ltd., registered in various countries. Other names mentioned are owned by their respective holders.
This press release contains statements that constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Ceragon’s management about Ceragon’s business, financial condition, results of operations, micro and macro market trends and other issues addressed or reflected therein. Examples of forward-looking statements include: projections of demand, revenues, net income, gross margin, capital expenditures and liquidity, competitive pressures, order timing, growth prospects, product development, financial resources, cost savings and other financial and market matters. You may identify these and other forward-looking statements by the use of words such as “may”, “plans”, “anticipates”, “believes”, “estimates”, “targets”, “expects”, “intends”, “potential” or the negative of such terms, or other comparable terminology.
Although we believe that the projections reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations therefrom will not be material. Such statements involve risks and uncertainties that may cause future results to differ materially from those anticipated. These risks and uncertainties include, but are not limited to, the effects of general economic conditions, the effect of the COVID-19 crisis on the global markets and on the markets in which we operate, including the risk of a continued disruption to our and our customers’, providers’, business partners and contractors’ business and operations as a result of the COVID-19 pandemic effects and the restrictions on operations created thereby, and of an adverse effect on our and our customers’ financial performance, cash flow, revenue and financial results, available cash and financing, and our ability to bill and collect amounts due from our customers as a result therefrom; the risk of components shortage due to the global shortage in semiconductors and chipsets, which could cause delays in deliveries of our products and delays in the deployment of wireless communication networks by our customers, slowdowns and other adverse effects on our industry; the risks relating to the concentration of a significant portion of Ceragon’s expected business in certain countries and particularly in India, where a small number of customers are expected to represent a significant portion of our revenues; risks associated with any failure to meet our product development timetable; the risk that the rollout of 5G services could take longer or be performed differently than anticipated and such other risks, uncertainties and other factors that could affect our results, as further detailed in Ceragon’s most recent Annual Report on Form 20-F and in Ceragon’s other filings with the Securities and Exchange Commission.
Such forward-looking statements, including the risks, uncertainties and other factors that could affect our results, represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. Such forward-looking statements do not purport to be predictions of future events or results and there can be no assurance that it will prove to be accurate. Ceragon may elect to update these forward-looking statements at some point in the future but the company specifically disclaims any obligation to do so except as may be required by law.
Ceragon’s public filings are available on the Securities and Exchange Commission’s website at www.sec.gov and may also be obtained from Ceragon’s website at www.ceragon.com.
Investor & Media Contact:Maya Lustig
Ceragon Networks
Tel. +972-54-677-8100
[email protected]
– Tables Follow –

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

Three months endedMarch 31,

2021

2020

Revenues

$     68,270

$     55,871

Cost of revenues

48,124

41,861

Gross profit

20,146

14,010

Operating expenses:

Research and development, net

7,410

7,290

Selling and marketing

8,290

8,273

General and administrative

4,093

4,456

Total operating expenses

 
$     19,793

$     20,019

Operating income (loss)

353

(6,009)

Financial expenses and others, net

1,051

308

Loss before taxes

(698)

(6,317)

Taxes on income

475

380

Equity loss in affiliates

–

183

Net loss

$     (1,173)

$     (6,880)

Basic net loss per share

 
$       (0.01)

$       (0.09)

Diluted net loss per share

 
$        (0.01)

 
$        (0.09)

Weighted average number of shares used in computing
basic net loss per share

82,583,760

80,764,932

Weighted average number of shares used in computing
diluted net loss per share

 
82,583,760

 
 
80,764,932

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S.

[…]

Read More…

NEW YORK, May 3, 2021 /PRNewswire/ — Future FinTech Group Inc. (NASDAQ: FTFT) (“hereinafter referred to as “Future FinTech”, “FTFT” or “the Company”), a leading blockchain-based e-commerce business and a fintech service provider, announced today that on April 28, 2021, Mr. Lei Peng, General Manager of Future Supply Chain Co., Ltd., a wholly-owned subsidiary of Future FinTech, attended the ‘2021 Chengdu Blockchain + Digital Cultural Creative Industry Development Conference’ held in the Pidu District of Chengdu, China.
At the conference, Mr. Peng provided a commitment to the Chengdu municipal government on the Company’s behalf to establish two wholly-owned subsidiaries in Chengdu city: Future Big Data (Chengdu) Co., Ltd., an enterprise to focus on blockchain big data and the development of a high-speed computing center, and Future Supply Chain (Chengdu) Co., Ltd., an entity to further advance the supply chain financial technology sector.
The conference covered such topics as Blockchain and Digital Cultural Innovation, Intellectual Property Rights Protection, and Blockchain Transactions and Circulation. In addition, ten blockchain enterprises, including the Company, jointly established the Chengdu Urban Blockchain Industry Alliance to promote the following:

The establishment of a film and television blockchain talent center,
A blockchain core technology R&D center,
A blockchain innovation and applied research center
A blockchain industry incubation center.

The conference was attended by industry elites, academicians, experts in the blockchain field, state ministries and municipal government officials.
Shanchun Huang, CEO of Future Fintech, commented, “We are in agreement with the conference’s viewpoint and also believe that the increasing evolution of blockchain technology will continue to be applied in many sectors including finance, culture, entertainment, media and intellectual property. This provides us with an excellent opportunity to help to transform and upgrade industries in China. Consequently, we will continue to invest in blockchain technology and big data with the dual goal of making a deep impact on society as well as to maximize returns for our shareholders.”
About Future FinTech Group Inc.
Future FinTech Group Inc. (“Future FinTech”, “FTFT” or the “Company”) is a leading blockchain e-commerce company and a service provider for financial technology incorporated in Florida. The Company’s operations include a blockchain-based online shopping mall platform, Chain Cloud Mall (“CCM”), a cross-border e-commerce platform (NONOGIRL), an incubator for blockchain based application projects and financial services for the supply chain industry. The Company is also engaged in the development of blockchain based e-Commerce technology as well as financial technology. For more information, please visit http://ftft.com/.
Safe Harbor Statement
Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.
All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2020 and our other reports and filings with SEC. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.
SOURCE Future FinTech Group Inc.

Related Links
http://ftft.

[…]

Read More…

By Colin Kellaher

Global payments platform Flywire Corp. on Monday made public its filing with the U.S. Securities and Exchange Commission for an initial public offering.
The Boston company’s filing indicates it plans to raise $100 million, although that figure is often used as a placeholder to calculate filing fees.
Flywire, whose current investors include Bain Capital, Spark Capital, Temasek Holdings and Goldman Sachs, in March said it had filed confidentially with the SEC for the planned IPO. Reuters in January had reported that the IPO could value the payments processor at about $3 billion.
Flywire said it has applied to list its shares on the Nasdaq Global Market under the symbol FLYW.

Write to Colin Kellaher at [email protected]

(END) Dow Jones Newswires
May 03, 2021 06:45 ET (10:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.

[…]

Read More…

DENVER–(BUSINESS WIRE)–May 3, 2021–
Palantir Technologies today announced the hiring of Dr William J. Kassler, MD, MPH, as its first US Government Chief Medical Officer, bringing years of clinical and public health expertise to Palantir as it continues its expansion in the private and public health sectors.
Dr. Kassler is joining Palantir from IBM Watson Health and worked throughout his career at the intersection of clinical care and population health. He will lead the Public Health and Life Sciences teams across Palantir’s USG and international business.

Over the past few years, Palantir has grown its healthcare business and in recent months made significant new senior hires with deep domain expertise in life sciences, pharmaceuticals, and public health. Dr. Kassler and the expanded team will continue to build on Palantir’s success in public and commercial healthcare around the globe, putting its technology to work to solve the world’s most important health problems.
“Palantir has played a key role in mitigating the global Covid-19 pandemic, supporting more than 100 organizations in their response to the pandemic, and helping the U.S. and the U.K with vaccine distribution,” said Shyam Sankar, Palantir’s COO. “Palantir software has also been used in drug discovery, biotechnology, scientific research, and to mitigate disparities in public health. Dr. Kassler will play a key role in ensuring our healthcare work continues to prosper.”
“Palantir’s ability to lead so many international public health initiatives from the start of this pandemic was truly impressive and serves as a model for the type of technology investments governments around the world need to make,” said Dr. Kassler. “I’m inspired by Palantir’s mission and team, and excited to get to work. To emerge from this pandemic stronger, society will need to make significant improvements to how we approach public health.”
Dr. Kassler was IBM Watson Health’s Deputy Chief Health Officer and Chief Medical Officer for Government Health & Human Services and led their population health efforts. Before joining the private sector, he was Chief Medical Officer for the New England Region of the Centers for Medicare and Medicaid Services (CMS), and the State Health Officer for the New Hampshire Department of Health and Human Services. Dr. Kassler started his career at the Centers for Disease Control and Prevention (CDC).
He received his MD from the University of Massachusetts Medical School, an MS in nutrition from Case Western Reserve University, and an MPH from the University of California, Berkeley. He completed a primary care internal medicine residency at Brown University and was a Robert Wood Johnson Clinical Scholar at the University of California, San Francisco.
About Palantir Technologies
Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at https://www.palantir.com.
Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding our healthcare business and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate contracts. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210503005142/en/
CONTACT: Lisa Gordon
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA COLORADO
INDUSTRY KEYWORD: DATA MANAGEMENT BIOTECHNOLOGY TECHNOLOGY HEALTH GENERAL HEALTH PHARMACEUTICAL RESEARCH SOFTWARE NETWORKS INTERNET SCIENCE
SOURCE: Palantir Technologies
Copyright Business Wire 2021.
PUB: 05/03/2021 06:30 AM/DISC: 05/03/2021 06:30 AM
http://www.businesswire.

[…]

Read More…

BOSTON, May 03, 2021 (GLOBE NEWSWIRE) — Flywire Corporation (“Flywire”), a global payments enablement and software company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Flywire intends to list its common stock on the Nasdaq Global Market under the ticker symbol “FLYW.”
Goldman Sachs & Co. LLC, J.P. Morgan, Citigroup and BofA Securities will act as lead book-running managers for the proposed offering.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at [email protected]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-800-831-9146 or by email at [email protected]; or BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department or by email at [email protected].
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Flywire
Flywire is a global payments enablement and software company. Flywire combines its proprietary global payments network, next-gen payments platform and vertical-specific software to deliver the most important and complex payments for clients and their customers.
Flywire leverages its vertical-specific software and payments technology to deeply embed within the existing A/R workflows for its clients across the education, healthcare and travel vertical markets, as well as in key B2B industries. Flywire also integrates with leading ERP systems, so organizations can optimize the payment experience for their customers while eliminating operational challenges.
Flywire offers its 2,250+ clients diverse payment methods in more than 130 currencies across 240 countries and territories around the world. The company is headquartered in Boston, MA, USA with global offices.
Contacts
Media Contacts:
Sarah [email protected]
Prosek [email protected]
Investor Relations Contact:
ICRflywireir@icrinc.

[…]

Read More…

CHAM, Switzerland, May 03, 2021 (GLOBE NEWSWIRE) — Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announced that it has submitted a formal application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”). NASDAQ is the second largest exchange by market capitalization worldwide and is home to many of the world’s best technology companies.
In connection with its application to list on NASDAQ, Bionovate will file a Form 20-F Registration Statement with the United States Securities and Exchange Commission (SEC). Acceptance for listing the Company’s shares is subject to approval based on several factors including satisfaction of minimum listing requirements for the NASDAQ Capital Market. The Company intends to satisfy all the applicable listing requirements. With the listing Bionovate is entering an important phase into a fast growing medical device market worldwide.
About Bionovate Technologies Corp.Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an ecosystem of medical devices and mobile applications to turn health care data into personal digital services with a great user experience on mobile devices. Innovations in this field are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide.
Safe Harbor StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.
Bionovate Technologies Corp.Gewerbestr. 106330 ChamSwitzerland
Press contact:Sandra MeyerTel: +41 581 01 02 02Mail: press@bionovate.

[…]

Read More…

“Dr. Natalie Dickson and Curtis Warfield each bring significant experience that will enhance our Board,” said David Chernow, Chairman of OneOncology’s Board of Managers. “Dr. Dickson is an incredible physician leader, and Curtis Warfield has a wealth of board, technology and payer experience in healthcare. I’m looking forward to working with both of them to enhance the delivery of cancer care and benefit the practice partners we serve.”     

Dr. Dickson is President and Chief Medical Officer for Tennessee Oncology, where she guides process improvement, regulatory affairs and safety initiatives. She is also skilled in stakeholder management, maintaining a cooperative working relationship along the healthcare continuum with staff, physicians, hospitals and payers. Her passion for improving the delivery of care for patients drives her focus on physician-led collaboration with technology vendors, pharmaceutical innovators and other organizations. As Tennessee Oncology leads in the implementation of alternative payment models, Dr. Dickson is focused on prioritizing quality initiatives, reducing unnecessary variation, and analyzing and sharing performance metrics. Dr. Dickson also has maintained an active hematology-oncology practice for the past 22 years.
Curtis Warfield, an accomplished C-suite executive, has served in senior roles with three Fortune 500 companies. In addition to his leadership role at Windham Advisors, he is also currently a board member of Texas Roadhouse, a publicly traded global brand, as well as the Chairman of its Nominating and Governance Committee.
Mr. Warfield, who is a U.S. Securities and Exchange Commission expert and a certified public accountant, has also served as part of the senior leadership team of Anthem, Inc., one of the nation’s largest health insurers with over $100 billion in revenues, from 2017 to 2019.  As a senior executive at HCA, the largest healthcare provider in the country, from 1997 to 2016 he held a variety of roles with the majority of his tenure as the Chief Executive Officer of NPAS, a healthcare services company.
With these additions, OneOncology’s nine-member Board of Managers consists of five physicians. Board members are Jeff Patton, MD, CEO; David Chernow, Chairman; Natalie Dickson, MD; Senator Bill Frist, MD; Edward Licitra, MD; Justin Sunshine; Jeff Vacirca, MD; Robbert Vorhoff; and Curtis Warfield.
About OneOncologyOneOncology is the national platform for independent community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven and patient-centric model. OneOncology is comprised of leading community oncology practices representing more than 550 providers practicing at more than 175 sites of care across the United States. To learn more, visit oneoncology.com or LinkedIn. 
SOURCE OneOncology

Related Links
https://oneoncology.

[…]

Read More…

Vote on extension resolution to be held on May 6, 2021
Vote on business combination and domestication to be adjourned
TORONTO and SANTA ROSA, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Bespoke Capital Acquisition Corp. (NASDAQ: BSPE) (TSX: BC.U) (TSX: BC.WT.U) today provided an update on the shareholder meeting scheduled for May 6, 2021 at 1:00 p.m. (EDT), to be held as a virtual-only meeting via live audio webcast online at https://virtual-meetings.tsxtrust.com/1123.
BCAC is completing the SEC review of the registration statement related to the proposed business combination with Vintage Wine Estates (“VWE”) and change in its jurisdiction of incorporation to Nevada. To accommodate the SEC review process, BCAC will hold a vote at the May 6th meeting on the extension of the permitted investment timeline to July 30, 2021, but adjourn the vote on the VWE acquisition and change in its jurisdiction of incorporation until BCAC’s registration statement is declared effective by the SEC. BCAC will circulate a new proxy card and hold the vote on such resolutions as promptly as practicable thereafter. BCAC currently expects to reconvene the meeting before the end of May.
The BCAC Board of Directors urges shareholders of record as of March 31, 2021 to vote the WHITE proxy card FOR the extension resolution on May 6, 2021.
Redemption Rights
Prior to 4:00 p.m. (EDT) on May 3, 2021, holders of Class A Restricted Voting Shares of BCAC have a right to deposit their shares for redemption in connection with the vote to approve an extension of the permitted timeline to complete the qualifying acquisition. BCAC previously agreed that it will allow any shareholder who previously submitted a redemption request to revoke the redemption until the redemption deadline.
BCAC reminds holders of Class A Restricted Voting Shares that they will also have a second redemption right that will extend for at least 20 business days after the final prospectus is filed with Canadian regulators and BCAC’s registration statement is declared effective by the SEC. Accordingly, shareholders will have a second opportunity to redeem their Class A Restricted Voting Shares prior to the completion of the transaction if they choose not to redeem at this time.
BCAC urges its shareholders to carefully review the S-4 registration statement filed with the SEC in connection with their consideration of the proposed transactions, including the most recent amendment filed on May 3, 2021. The registration statement is available free of charge at www.sec.gov and www.sedar.com, as well as at www.bespokespac.com/investor-relations and www.vintagewineestates.com/investors.
Forward-Looking Statements
Some of the statements contained in this document are forward-looking statements within the meaning of U.S. securities laws and forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are all statements other than those of historical fact, and generally may be identified by the use of words such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “future,” “intend,” “may,” “model,” “outlook,” “plan,” “pro forma,” “project,” “seek,” “should,” “will,” “would” or other similar expressions that indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding closing of the investment and the transaction and the shareholder meeting and its business. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of BCAC’s management and are not guarantees of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ materially from those contained in or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of BCAC. Factors that could cause actual results to differ materially from the results expressed or implied by such forward-looking statements include, among others: the effect of economic conditions on the industries and markets in which VWE operates, including financial market conditions, fluctuations in prices, interest rates and market demand; the ability of the parties to successfully or timely consummate the transactions, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transactions or that the approval of the shareholders of BCAC or VWE is not obtained; failure to realize the anticipated benefits of the transactions; risks relating to the uncertainty of the projected financial information; the effects of competition on VWE’s future business; risks related to the organic and inorganic growth of VWE’s business and the timing of expected business milestones; the amount of redemptions, if any, made by BCAC’s shareholders in connection with the transactions; the requirement for Wasatch to fund the subscription price on closing; the potential adverse effects of the ongoing COVID-19 pandemic on VWE’s business and the U.S. economy; declines or unanticipated changes in consumer demand for VWE’s products; the impact of environmental catastrophe, natural disasters, disease, pests, weather conditions and inadequate water supply on VWE’s business; VWE’s significant reliance on its distribution channels; potential reputational harm to VWE’s brands from internal and external sources; possible decreases in VWE’s wine quality ratings; possible departures from VWE’s or the combined company’s senior management team; integration risks associated with acquisitions; changes in applicable laws and regulations and the significant expense to VWE of operating in a highly regulated industry; VWE’s and the combined company’s ability to make payments on its indebtedness; and those factors discussed in documents of BCAC filed, or to be filed, with the U.S. Securities and Exchange Commission (“SEC”) or Canadian securities regulatory authorities. There may be additional risks that BCAC does not know or that BCAC currently believes are immaterial that could also cause actual results to differ from those expressed in or implied by these forward-looking statements. In addition, forward-looking statements reflect BCAC’s expectations, plans or forecasts of future events and views as of the date of this press release. BCAC undertakes no obligation to update or revise any forward-looking statements contained herein, except as may be required by law. Accordingly, undue reliance should not be placed upon these forward-looking statements.
Important Information and Where to Find It
In connection with the transactions, BCAC has filed (1) with the SEC a preliminary consent solicitation statement/prospectus and amendments thereto (the “Consent Solicitation Statement/Prospectus”), which includes a preliminary consent solicitation statement of VWE and a preliminary prospectus of BCAC to be distributed to BCAC shareholders and VWE shareholders; (2) with Canadian securities regulatory authorities a preliminary non-offering prospectus (the “Canadian Prospectus”) under Canadian securities laws to be distributed to BCAC shareholders; and (3) with Canadian securities regulatory authorities a management proxy circular (the “Proxy Circular”) under Canadian securities laws distributed to BCAC shareholders. INVESTORS AND OTHER SECURITY HOLDERS ARE URGED TO READ THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, THE CANADIAN PROSPECTUS AND THE PROXY CIRCULAR, ANY AMENDMENTS THERETO AND ANY OTHER DOCUMENTS FILED BY BCAC WITH THE SEC OR CANADIAN SECURITIES REGULATORY AUTHORITIES CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BCAC, VWE AND THE TRANSACTIONS. When available, investors and security holders may obtain free copies of these documents and other documents, with respect to those filed with the SEC, at www.sec.gov, and with respect to those filed with the Canadian securities regulatory authorities, at www.sedar.com, or by directing a request to BCAC at 595 Burrard Street, Suite 2600, Three Bentall Centre, Vancouver, BC V7X1L3.
INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, CANADIAN SECURITIES REGULATORY AUTHORITIES OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING THEREOF OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
Participants in the Solicitation
BCAC and VWE and their respective directors and certain of their respective executive officers and other members of management and employees may be considered participants in the solicitation of proxies or consents with respect to the transactions. Information about the directors and executive officers of BCAC and VWE and a description of their direct and indirect interests, by security holdings or otherwise, are set forth in the Consent Solicitation Statement/Prospectus, the Canadian Prospectus and the Proxy Circular. Additional information may be set forth in other relevant materials to be filed with the SEC and Canadian securities regulatory authorities regarding the transactions. Security holders, potential investors and other interested persons should read these materials carefully and in their entirety when they become available before making any voting or investment decisions. You may obtain free copies of these documents as indicated above.
No Offer or Solicitation
This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of securities in any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of the Securities Act of 1933 or an exemption therefrom.
Contacts:
Investors
Mark HarmsBespoke Capital Partners [email protected] +44-207-016-8050
or
[email protected] 
Media
Alecia PulmanBespokePR@icrinc.

[…]

Read More…

MELVILLE, N.Y., May 03, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings. The filing of the Form 10-K has resulted in the removal of the “stop sign” from the OTC Markets website with regard to the Company, indicating that BioRestorative now has current public information available.
Lance Alstodt, Chairman and CEO, stated “I am very excited that, after only 5 months post- Chapter 11, we are now current in all of our reporting requirements with the SEC. It is a testament to the execution of our team and advisors, having met an aggressive timetable in achieving this meaningful milestone. We believe that we are now very well positioned to pursue funding opportunities to initiate our phase 2 clinical trial, which the FDA has granted us approval to begin. Additionally, we will advance our metabolics program simultaneously, continuing to build fundamental value within our two platform technologies.
The Company is now at a critical inflection point where value creation should largely be tied to the advancement of our clinical programs. I’m pleased with our team’s discipline and focus, accomplishing so much in a short period of time. Among the many goals we have met: we have right sized the organization with a more efficient infrastructure reducing our monthly burn rate; we have recapitalized our balance sheet to include a more flexible set of future funding opportunities; and we have added to our team of experts and advisors to match our challenges with the right set of human resources. Leveraging all of these corporate activities will position BioRestorative as a biotechnology company with many future operational/clinical catalysts to drive value to our shareholders. I’m passionate about our technology and our ability to prove and validate what could be paradigm shifting events in the sectors where we focus.”
Francisco Silva, Vice President of Research and Development, added, “Achieving full reporting compliance was an important milestone for the company; we can now turn our attention to initiating our clinical programs. We expect to address in-house clinical manufacturing capabilities for both our ThermoStem® metabolic and BRTX-100® disc/spine programs. We look forward to achieving our clinical targets and driving value based on clinical catalysts”.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company’s latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:Email: ir@biorestorative.

[…]

Read More…

Stock tip! Hometown International, Inc., is a company that consists of one Italian delicatessen, Your Hometown Deli, founded by a high-school wrestling coach in Paulsboro, New Jersey. On a typical day, Hometown’s sales total about eighty dollars. A few years ago, during the current bull market, Hometown decided to go public. The Securities and Exchange Commission was leery: Hometown’s major shareholders include mysterious entities based in Macao; plus, it is just one deli. When Hometown submitted its I.P.O. paperwork, the S.E.C. warned, “Please revise your disclosure throughout your filing to state that you are a shell company.” Hometown took exception to this. Shell companies don’t actually do business. Hometown, on the other hand, was procuring meats and sprucing up its storefront. “Various sinks and tables were purchased,” Hometown responded. “There is also a cable phone line available to use.” The I.P.O. went ahead. Revenue declined. The stock price did not. Hometown is currently valued at two billion dollars.

By now, even people who don’t know their N.F.T.s from their U.F.O.s can opine that we’re in a stock-market bubble. Hypotheses for what was going on with Hometown have abounded. It was a “pump and dump.” Or a “box job.” Maybe it was just a late-boom amusement: too much money, too much free time. A backdoor “SPAC”? This, essentially, is how one big Hometown investor in Hong Kong has explained it. (Hometown has declined to comment, although its wrestling-coach founder, Paul Morina, has been spotted at tournaments.) Hometown wasn’t GameStop-level popular—the number of shares traded was low. Still, real people were willing to pay for it. David Einhorn, the president of the hedge fund Greenlight Capital, cited Hometown in a letter to his investors. “From a traditional perspective, the market is fractured and possibly in the process of breaking completely,” he said. He added, “The pastrami must be amazing.”
But what if shareholders just believe in the business plan? Perhaps the pastrami actually is amazing. To find out, one prospective investor recently set out to analyze the fundamentals. A visit was paid to the deli, a small concrete building near some petroleum refineries. Two friendly women were on duty. It was the lunch rush, but there were no other customers. Every now and then, callers availed themselves of the cable phone line—mainly pranksters asking about buying stock. The menu was expansive, if somewhat aspirational; the chicken parm was unavailable, because the deli was out of chicken. Same for the roast beef, which needed a day to cook. The prospective investor ordered a sampling of hoagies. They were prepared in the back, out of sight. One or more of the various sinks could be heard running. Then the product emerged, wrapped in white paper.

A private valuation was arranged. To insure a knowledgeable analysis, the hoagies were brought to an Italian specialty store ninety minutes up the turnpike. Ron Ferreira, the manager at Benvenuti, in Garwood, volunteered to give ratings. He’d heard, vaguely, of Hometown, but he didn’t know the stock price. He did, however, know sandwiches. “I’ve been in this kind of work for forty years,” Ferreira said—Sbarro, delis, a local place called Antonio’s Mozzarella Factory. He ran his own shop for sixteen years. “I appreciate when it’s done right,” he said. For experimental integrity, a classic Italian hoagie from Wawa, the convenience chain popular in the Philadelphia area, served as the control.

First up: the cheesesteak. Ferreira, who had a shaved head and wore a black button-down, took a bite. “It’s got that good Philly bread,” he said. “By that I mean it’s got a crust to it, not too hard, and it has a chew. It’s soft, but not fall-apart soft.” The meat was solid, even at ninety minutes old. Rating: BUY.

“No! Not social reëntry!”

Cartoon by Julia Suits
The next two sandwiches, Italian and Sicilian combos, were fine but lacked zing.“That’s cheap-ass vinegar,” Ferreira said. “Bread is good, there’s plenty of meat. I think the dressing falls short. I’d give it a seven.” Rating: HOLD.
The final hoagie was a turkey with cheese. Ferreira was satisfied but not inspired. “It’s just a sandwich,” he said. Rating: MODERATE BUY.
Ferreira judged the sandwiches to be Wawa-level quality—pretty good. But there were red flags. “Those pickles are cheap pickles, first of all,” he said. “If you’re a deli, get a fuckin’ pickle guy.” Then there were the supply-chain issues. “For them not to have chicken on a weekend? I don’t know, it doesn’t equate,” he said. “And they’re cooking the roast beef, and it’ll be ready tomorrow?” He went on, “It doesn’t sound kosher to me.” Asked for a target valuation for investors, Ferreira did some mental calculation and declared, “You’ve gotta look at the numbers. But it could be a fifty-thousand-dollar business.”
Analysis done, Ferreira prepared for the dinner crowd—there was balsamic spread to make, prosciutto di Parma to slice, chicken cutlets to bread. The stock market was about to close. Hometown was up another nine per cent.

[…]

Read More…

Enable files annual, quarterly and other reports and other information with the U.S. Securities and Exchange Commission (SEC).

[…]

Read More…

… risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 24, …

[…]

Read More…

DALLAS, May 03, 2021 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE: WHG) announced that on May 2, 2021, its Board of Directors (“Board”) adopted a limited-duration Shareholder Rights Agreement (the “Rights Agreement”) and declared a distribution of one right for each outstanding share of common stock. The Rights Agreement is effective immediately and will expire on May 1, 2022 or earlier, as provided in the Rights Agreement.
The adoption of the Rights Agreement is intended to enable all Westwood shareholders to realize the full potential value of their investment in the company and to protect the interests of the company and its shareholders by reducing the likelihood that any person or group gains control of Westwood through open market accumulation or other tactics without paying an appropriate control premium. In addition, the Rights Agreement provides the Board with time to make informed decisions that are in the best long-term interests of Westwood and its shareholders. It does not deter the Board from considering any offer that is fair and otherwise in the best interest of Westwood shareholders.
The Rights Agreement is similar to other rights plans adopted by publicly held companies. The rights will be exercisable only if, following today’s announcement, a person or group (each, an “acquiring person”) acquires beneficial ownership of 10% (20% for passive institutional investors) or more of Westwood’s outstanding common stock in a transaction not approved by Westwood’s Board. In that case, each holder of a right (other than the acquiring person, whose rights will become void and will not be exercisable) will be entitled to purchase, at the then-current exercise price, additional shares of Westwood common stock at a 50% discount. The Board, at its option, may exchange each right (other than rights owned by the acquiring person that have become void) in whole or in part, at an exchange ratio of one share of Westwood common stock per outstanding right, subject to adjustment. Except as provided in the Rights Agreement, the Board is entitled to redeem the rights at $0.001 per right. The record date for the rights distribution is May 12, 2021.
Any shareholders with beneficial ownership of 10% or more of Westwood’s outstanding common stock (20% for passive institutional investors) prior to this announcement are generally grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Agreement.
Additional information regarding the Rights Agreement will be contained in a current report on Form 8-K to be filed by Westwood with the U.S. Securities and Exchange Commission.
Sidley Austin LLP is acting as legal counsel to Westwood.
About Westwood Holdings Group
Westwood Holdings Group, Inc. is an investment management boutique and wealth management firm based in Dallas, Texas.
Westwood offers high-conviction equity and outcome-oriented solutions to institutional investors, private wealth clients and financial intermediaries. The firm specializes in two distinct investment capabilities: U.S. Value Equity and Multi-Asset, available through separate accounts, the Westwood Funds® family of mutual funds and other pooled vehicles. Westwood benefits from significant, broad- based employee ownership and trades on the New York Stock Exchange under the symbol “WHG.” For more information, please visit westwoodgroup.com.
Contact:
Investors
Westwood Holdings Group, Inc.Terry ForbesChief Financial Officer and Treasurer(214) 756-6900
Media
Gagnier CommunicationsDan Gagnier / Jeffrey Mathews(646) 569-5897Westwood@gagnierfc.

[…]

Read More…

RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Morphine injection for the year ended December 31, 2020, were $2.3 million.
Amphastar’s CEO and President, Dr. Jack Zhang, commented: “The FDA’s approval of Morphine injection shows the Company’s continued commitment and ability to manufacture high quality injection products.”
Pipeline Information
The Company currently has five ANDAs on file with the FDA targeting products with a market size of approximately $2.4 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and seven generic products in development targeting products with a market size of approximately $10 billion. This market information is based on IQVIA data for the 12 months ended March 31, 2021. The Company is currently developing multiple proprietary products with injectable and intranasal dosage forms.
Amphastar’s Chinese subsidiary, ANP, currently has 17 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, Primatene Mist®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.
Noted products are trademarks or registered trademarks of their respective owners.
Contact Information:
Amphastar Pharmaceuticals, Inc.

[…]

Read More…